Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

About this update from Niagen Bioscience, Inc.

Virtual Q&A session to discuss the recently launched pharma program, the Company's leadership in NAD+ science, and provide updates on Niagen Bioscience's business LOS ANGELES, July 09, 2026 --( BUSINESS WIRE )-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the Company's continued leadership in NAD+ science, and provide updates on Niagen Bioscience's business. The conversation will be moderated by Valter Pinto, Managing Director of KCSA Strategic Communications, and will include a live question-and-answer session. Event Details A live webcast of the event will be available through the registration link above. A replay of the presentation will be made available on the Company's investor relations website following the event. For additional information on Niagen Bioscience, visit www.niagenbioscience.com . About Niagen Bioscience Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated molecule.

View stock analysis, news, and events for Niagen Bioscience, Inc.